TDO2
Tryptophan 2,3-dioxygenase
Also known as: T23O_HUMAN, TDO, TPH2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P48775
- Gene
- TDO2
- Ensembl
- ENSG00000151790
- Chromosome
- 4
- Canonical length
- 406 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Plasma membrane,Primary cilium,Basal body,Cytosol
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
This gene encodes a heme enzyme that plays a critical role in tryptophan metabolism by catalyzing the first and rate-limiting step of the kynurenine pathway. Increased activity of the encoded protein and subsequent kynurenine production may also play a role in cancer through the suppression of antitumor immune responses, and single nucleotide polymorphisms in this gene may be associated with autism. [provided by RefSeq, Feb 2012]
Canonical amino-acid sequenceUniProt
406 residues, UniProt reviewed canonical sequence.
>P48775|TDO2
1 MSGCPFLGNN FGYTFKKLPV EGSEEDKSQT GVNRASKGGL IYGNYLHLEK VLNAQELQSE
61 TKGNKIHDEH LFIITHQAYE LWFKQILWEL DSVREIFQNG HVRDERNMLK VVSRMHRVSV
121 ILKLLVQQFS ILETMTALDF NDFREYLSPA SGFQSLQFRL LENKIGVLQN MRVPYNRRHY
181 RDNFKGEENE LLLKSEQEKT LLELVEAWLE RTPGLEPHGF NFWGKLEKNI TRGLEEEFIR
241 IQAKEESEEK EEQVAEFQKQ KEVLLSLFDE KRHEHLLSKG ERRLSYRALQ GALMIYFYRE
301 EPRFQVPFQL LTSLMDIDSL MTKWRYNHVC MVHRMLGSKA GTGGSSGYHY LRSTVSDRYK
361 VFVDLFNLST YLIPRHWIPK MNPTIHKFLY TAEYCDSSYF SSDESDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TDO2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 740 nTPM
Expression across tissuesHPA
Tissue
- liver: 740 nTPM
- appendix: 16 nTPM
- urinary bladder: 7.1 nTPM
- small intestine: 5.5 nTPM
- pituitary gland: 3.8 nTPM
- duodenum: 3.4 nTPM
Single-cell type
- hepatocytes: 167 nCPM
- brain excitatory neurons: 19 nCPM
- cholangiocytes: 19 nCPM
- gonadotrophs: 7.8 nCPM
- hepatic stellate cells: 6.5 nCPM
- brain inhibitory neurons: 4.8 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 2.3 nTPM
- midbrain: 1.8 nTPM
- white matter: 1 nTPM
- hippocampal formation: 0.6 nTPM
- amygdala: 0.4 nTPM
- basal ganglia: 0.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TDO2.
Disease | AllUniProt
Conditions TDO2 is implicated in, by any mechanism.
- Hypertryptophanemia (HYPTRP) MIM:600627
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.04
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.22
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- L-tryptophan catabolic process to kynurenine
- protein homotetramerization
- response to cortisol
- response to ethanol
- L-tryptophan catabolic process to acetyl-CoA
- response to nitroglycerin
Molecular functions
- amino acid binding
- heme binding
- identical protein binding
- L-tryptophan 2,3-dioxygenase activity
- metal ion binding
- oxygen binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Tryptophan/Indoleamine 2,3-dioxygenase-like
- Tryptophan 2,3-dioxygenase
- Tryptophan 2,3-dioxygenase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TDO2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TDO2 as an antibody target. Whether an autoantibody or antibody against TDO2 could matter depends on whether native TDO2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TDO2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TDO2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...